Gender inequalities in depression/anxiety and the consumption of psychotropic drugs: Are we medicalising women’s mental health?

Amaia Bacigalupe,Unai Martín

DOI: https://doi.org/10.1177/1403494820944736

2020-08-05

Scandinavian Journal of Public Health

Abstract:Aims: Clinical studies show that women are more likely to be diagnosed with depression and anxiety, and to consume prescribed psychotropic drugs. Applying an intersectional perspective that considers age, education and social class, the present study assesses gender inequalities in the diagnosis of depression/anxiety and in psychotropic consumption. Methods: We analysed data from the 2018 Basque Country Health Survey (Spain; n=8014). Prevalence rates of poor mental health, diagnosis of depression/anxiety and psychotropic consumption were calculated for each sex by age and socio-economic status. Poisson regression models were calculated to estimate PRs of these variables in women, adjusted for age, mental health status and health-care visits, and for diagnosis of depression/anxiety in the case of psychotropic drug consumption. Results: Women were 2.48 times more likely than men to be diagnosed with depression or anxiety, and this difference remained significant after adjustments (prevalence ratio (PR)=1.86; 95% confidence interval (CI) 1.40–2.47). Women also took significantly more prescribed psychotropic drugs, even controlling for their poorer mental health, their higher prevalence of diagnosis and their more frequent health-care visits (PR=1.52; 95% CI 1.28–1.82). No gender inequalities were observed in those younger than 45 or with the highest level of education. Conclusions: Gender inequalities in the diagnosis and prescription of psychotropic drugs exist, and these cannot be explained by differences in mental-health status or health-care visit frequency. It seems, then, that medicalisation of mental health is occurring among women. Further evidence about the mechanisms that underlie the results is crucial to design truly gender-sensitive health policies that reduce medicalisation of women’s mental health.

public, environmental & occupational health

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore the manifestations of gender inequality in the diagnosis of depression and anxiety disorders and the use of psychotropic drugs, and to analyze whether these differences can be explained by differences in mental health status or the frequency of using medical services. In addition, from an intersectional perspective, the study also considers the influence of factors such as age, education level and social class on gender inequality, in order to explore the potential mechanisms of the medicalization of women's mental health.

Specifically, the study aims to:
1. Analyze the gender differences between men and women in the prevalence of depression and anxiety disorders and the use of psychotropic drugs.
2. Explore whether these gender differences can be explained by adjusting mental health status and the frequency of medical service visits.
3. Analyze the manifestations of gender differences in different age groups, education levels and social classes from an intersectional perspective, in order to reveal the impact of social and gender inequality on the medicalization of women's mental health.

The study found that even after controlling for mental health status and the frequency of medical service visits, women are still significantly more likely to be diagnosed with depression or anxiety disorders than men, and the proportion of women using prescribed psychotropic drugs is also higher. These results indicate that there is an over - medicalization of women's mental health, especially more obvious in the elderly population and groups with lower socioeconomic status. This suggests that it is necessary to further explore the specific mechanisms leading to these results in order to design truly gender - sensitive health policies and reduce the medicalization of women's mental health.